Key facts
- It has raised $116.0M; the latest was Reverse Merger ($288.0M) in Nov 2024.
- Notable investors include Hongshan Capital Group, Highlight Capital, South China Venture Capital, MSA Capital, Wuxi Capital Group — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Cullgen
- ·The full record, as it builds
Funding rounds
No funding rounds for Cullgen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cullgen
Cullgen Inc is clinical-stage biopharmaceutical company. The company is engaged in the development of medicines for the treatment of diseases lacking effective therapeutic approaches. The company utilizes its technology platform, uSMIT, featuring novel E3 ligands, to build the next generation of targeted protein degraders and to discover and advance therapeutics for the treatment of cancer and other diseases. The products in the company's pipeline include Degrader TRK, Degrader GSPT1, DAC, and others.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2018
- Employees
- 115
- Website
- cullgen.com/
- Ownership
- Privately Held (backing)
Cullgen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cullgen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cullgen in its N-PORT filings yet. We sweep new filings monthly.